A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL)

CONCLUSIONS: All adverse effects were manageable and none resulted in patient death. In conclusion, the nanoparticle albumin-bound paclitaxel + carboplatin + bevacizumab combination is favorable and well tolerated in Japanese patients as first-line treatment for advanced non-squamous non-small cell lung cancer.PMID:38594880 | DOI:10.1093/jjco/hyae044

Source: Clinical Lung Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Naoyuki Nogami Toshio Kubo Akihiro Bessho Makoto Sakugawa Satoshi Ikeo Toshihide Yokoyama Nobuhiko Seki Ryosuke Ochiai Nobukazu Fujimoto Shuji Murakami Kyoichi Kaira Toshiyuki Harada Daizo Kishino Yuichi Takiguchi Tsuneo Shimokawa Katsuyuki Kiura Natsumi Source Type: research